Clinical trial
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
NCT05766813 is registered in ClinicalTrials.gov with Intra-Cellular Therapies, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 13, 2023
- Completion date
- November 4, 2025
- Enrollment
- 79 (actual)
- Sites
- 35
Conditions
As the registry lists them; a condition with its own page is linked.